Navigation Links
Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Date:8/19/2007

of Genasense plus Dacarbazine Compared with Dacarbazine Alone in Patients with Advanced Melanoma". This trial will seek to evaluate the effectiveness of the Genasense/dacarbazine combination in patients identified in the preceding randomized trial of dacarbazine with or without Genasense (known as GM301) as having derived greatest benefit. AGENDA seeks to enroll patients using a readily available biomarker that multiple studies have confirmed as the most powerful indicator of prognosis. The trial will enroll approximately 300 patients and will be conducted at sites in North America, Europe and Australia. In July 2007, the Company announced that the European Medicines Agency indicated that approval of Genasense in melanoma will require the conduct of another clinical study, and the new trial is intended to address this requirement.

Chronic Lymphocytic Leukemia (CLL)

The Company announced that it will request review of the non-approvable decision by the Food and Drug Administration (FDA) for the New Drug Application (NDA) for Genasense in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Following FDA's established Dispute Resolution Process, Genta will submit its request to Dr. Steven Galson, Director of FDA's Center for Drug Evaluation and Research (CDER), and the Company anticipates a decision from CDER in the second half of 2007.

"Named-Patient" Distribution Will Provide Patient Access to Genasense(R) and Ganite(R)

While the AGENDA trial is ongoing, Genta has elected to continue to provide both Genasense (oblimersen sodium) and Ganite(R) (gallium nitrate injection) on a compassionate-use/named patient basis. Genta established this program via a collaboration with IDIS, a U.K.-based company that will distribute the drug in territories outside the United States upon physician request for a specific patient. Going forward, the Company will levy a charge and record revenue for the provision of both agents under this prog
'/>"/>

SOURCE Genta Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
2. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Sept. 22, 2014 Decision Resources Group finds that ... expected to be worth $2 billion (U.S. dollars), increasing at ... next five years (to 2018). This growth comes as ... in 2013 and 4.9 percent expected over the next three ... is small but highly competitive. The pharmaceutical market is dominated ...
(Date:9/22/2014)... -- Persistence Market Research ( http://www.persistencemarketresearch.com/ ) ... Ophthalmic Devices: Asia to Witness ... at USD 29,171.5 million in 2014 and is expected ... to 2020, to reach an estimated value of USD ... Market Study on Ophthalmic Devices:  Asia  to ...
(Date:9/22/2014)... , Sept. 22, 2014  AVT, Inc. (OTC ... retailing systems and custom vending machines, announced today that ... Unit. This new, smaller sized unit is designed for ... practices. According to industry statistics, there are ... Opticwash is the world,s first automated kiosk ...
Breaking Medicine Technology:Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 2Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5Opticwash Pro Enables Optical Retailers to Generate New Revenues and Customer Traffic through a Unique Eyeglass Cleaning System 2
... LAKES, N.J., Dec. 29 BD (Becton, Dickinson and Company) (NYSE: ... would present at the following investor healthcare conferences in January: , , ... 6, 2010, 9:15 a.m. ET, 28th ... 6:30 p.m. ET, , A live webcast of BD,s ...
... PALM CITY, Fla., Dec. 29 Connectyx Technologies Holdings Group, ... a National RV Owners Community as a marketing partner to ... over one million members and more than 3,400 individual club ... The RV Club provides its membership with essential services ranging ...
Cached Medicine Technology:BD to Present at Investor Healthcare Conferences 2Connectyx Announces MedFlash Sales Partnership with National Recreational Vehicle Club 2Connectyx Announces MedFlash Sales Partnership with National Recreational Vehicle Club 3
(Date:9/23/2014)... September 23, 2014 Ale Gicqueau, President ... on Advanced Data Visualization for Clinical Trials at the ... in San Francisco on Friday, September 26, 2014. ... volunteers. Since its inception, PhUSE has expanded from its ... a global platform for the discussion of topics encompassing ...
(Date:9/23/2014)... 23, 2014 WetKeys Washable Keyboards announces ... in their industrial keyboards line. Labeled ... to last longer in heavy-duty industrial computing for the ... where grease and oil can destroy usability or cause ... constant threat to the longevity of computer equipment and ...
(Date:9/23/2014)... September 23, 2014 With the emergence ... sale of all tobacco products, retail chains are transforming ... services to patients, customers, and shoppers. In this capacity, ... of retail pharmacy healthcare to share their knowledge on ... to know to coordinate care with other colleagues inside ...
(Date:9/23/2014)... Névo takes a bold step forward in fitness ... activity tracking and phone notifications for a fashion conscious ... and more. , http://www.nevowatch.com , “Today, ... their busy lives to look and feel better. The ... results, but until now, style played a distance second ...
(Date:9/23/2014)... 23, 2014 Published by Nationwide Lifts, the ... to take charge of their mobility in a new way, ... impactful. Stair lifts are that equipment and can ... in the elevator business, I’ve seen so many ... or a loved one with mobility issues,” said Andy Darnley, ...
Breaking Medicine News(10 mins):Health News:Clinovo Sponsors and Presents at Pharmaceutical Users Software Exchange (PhUSE) SDE in San Francisco 2Health News:WetKeys Announces New Oil Resistant Keyboard for Industrial Computing, Food Processing Plants, Automotive Factories and Machine Shops 2Health News:WetKeys Announces New Oil Resistant Keyboard for Industrial Computing, Food Processing Plants, Automotive Factories and Machine Shops 3Health News:WetKeys Announces New Oil Resistant Keyboard for Industrial Computing, Food Processing Plants, Automotive Factories and Machine Shops 4Health News:WetKeys Announces New Oil Resistant Keyboard for Industrial Computing, Food Processing Plants, Automotive Factories and Machine Shops 5Health News:Retail Pharmacies at the Forefront of Primary Care Innovation 2Health News:Nevo changes the face of fitness wearables with an analogue watch combining activity tracking, phone notifications, and LED goal progress indicators for active lifestyles 2Health News:Nevo changes the face of fitness wearables with an analogue watch combining activity tracking, phone notifications, and LED goal progress indicators for active lifestyles 3Health News:Nationwide Lifts, America’s Leader in Home Elevators, Is Proud to Announce the Release of Its First Book, “Stair Lifts: Move Up, Not Out!” 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: